HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of “Hold” from Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has been assigned a consensus recommendation of “Hold” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $16.80.

Several research analysts recently weighed in on HCM shares. Wall Street Zen lowered HUTCHMED from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Bank of America lowered their target price on HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research note on Tuesday, March 10th. Weiss Ratings downgraded HUTCHMED from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 1st. Finally, Morgan Stanley set a $13.60 price target on shares of HUTCHMED in a research report on Thursday, May 28th.

HUTCHMED Price Performance

Shares of NASDAQ:HCM opened at $10.63 on Wednesday. The company’s fifty day moving average is $13.35 and its two-hundred day moving average is $14.00. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.96 and a quick ratio of 4.83. HUTCHMED has a 12-month low of $10.40 and a 12-month high of $19.50.

Institutional Investors Weigh In On HUTCHMED

Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. grew its holdings in shares of HUTCHMED by 8.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock valued at $1,413,000 after acquiring an additional 7,342 shares in the last quarter. Jane Street Group LLC grew its stake in HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after purchasing an additional 124,771 shares in the last quarter. Ameriprise Financial Inc. increased its position in HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after purchasing an additional 698 shares during the last quarter. Bank of America Corp DE raised its stake in shares of HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after purchasing an additional 3,035 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of HUTCHMED by 19.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 25,046 shares of the company’s stock valued at $377,000 after buying an additional 4,116 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.